Radioiodinated antibody targeting of the HER-2/neu oncoprotein

被引：19
|
作者：
Xu, FJ
Yu, YH
Bae, DS
Zhao, XG
Slade, SK
Boyer, CM
Bast, RC
Zalutsky, MR
机构：
[1] UNIV TEXAS,MD ANDERSON CANCER CTR,DIV MED,HOUSTON,TX 77030
[2] DUKE UNIV,MED CTR,DEPT RADIOL,DURHAM,NC 27710
[3] DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710
来源：
NUCLEAR MEDICINE AND BIOLOGY | 1997年 / 24卷 / 05期
关键词：
c-erbB-2 (HER-2/neu); ovarian cancer; monoclonal antibody; radioiodination; tumor;
D O I：
10.1016/S0969-8051(97)00065-6
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
The HER-2/neu oncogene encodes a 185 kDa phosphoglycoprotein that is overexpressed in breast, ovarian and other cancers. Seven monoclonal antibodies reactive with this oncoprotein were labeled with I-131. In vitro experiments with SKOv3 9002-18 cells determined binding affinity, internalization and degradation. The biodistribution of these antibodies in comparison to I-125-labeled nonspecific antibody was measured in athymic mice with SKOv3 9002-18 ovarian carcinoma xenografts. Antibody 520C9 exhibited the highest and most specific retention in tumor, peaking at 17.4 +/- 5.6% ID/g at 24 h. (C) 1997 Elsevier Science Inc.
引用
收藏
页码：451 / 459
页数：9
相关论文
共 50 条
  • [21] HER-2 NEU-TARGETING GENE-THERAPY - A REVIEW
    HUNG, MC
    MATIN, A
    ZHANG, YJ
    XING, XM
    SORGI, F
    HUANG, L
    YU, DH
    GENE, 1995, 159 (01) : 65 - 71
  • [22] Targeting HER-2/neu overexpression:: transcriptional repression of HER-2/neu by adenovirus type 5 E1A as a cancer gene therapy
    Hung, MC
    Ueno, NT
    22ND CONGRESS OF THE INTERNATIONAL ASSOCIATION FOR BREAST CANCER RESEARCH, 1999, : 85 - 95
  • [23] Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer
    Nishio, Yoshitaka
    Yamada, Yoshiaki
    Kokubo, Hiroto
    Nakamura, Kogenta
    Aoki, Shigeyuki
    Taki, Tomohiro
    Honda, Nobuaki
    Nakagawa, Atsuko
    Saga, Shinsuke
    Hara, Kazuo
    UROLOGY, 2006, 68 (01) : 110 - 115
  • [24] Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer
    Carney, WP
    Neumann, R
    Lipton, A
    Leitzel, K
    Ali, S
    Price, CP
    CLINICAL CHEMISTRY, 2003, 49 (10) : 1579 - 1598
  • [25] Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours
    Pallud, C
    Guinebretiere, JM
    Guepratte, S
    Hacene, K
    Neumann, R
    Carney, W
    Pichon, MF
    ANTICANCER RESEARCH, 2005, 25 (2B) : 1433 - 1440
  • [26] EXPRESSION OF THE C-ERBB-2 (HER-2/NEU) ONCOPROTEIN IN HUMAN PROSTATIC-CARCINOMA
    KUHN, EJ
    KURNOT, RA
    SESTERHENN, IA
    CHANG, EH
    MOUL, JW
    JOURNAL OF UROLOGY, 1993, 150 (05): : 1427 - 1433
  • [27] HER-2/neu testing guidelines
    Masood, S
    LABORATORY MEDICINE, 2000, 31 (03) : 129 - 130
  • [28] Her-2/neu and breast cancer
    Kaptain, S
    Tan, LK
    Chen, BY
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2001, 10 (03) : 139 - 152
  • [29] HER-2/neu in bladder carcinoma
    Tommasi, S
    Ditonno, P
    Sisto, MR
    Paradiso, A
    Gentile, A
    Ricco, R
    Schittulli, F
    Jacobellis, U
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 8 (05) : 957 - 961
  • [30] Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice
    Jacob, Jennifer
    Radkevich, Olga
    Forni, Guido
    Zielinski, John
    Shim, David
    Jones, Richard F.
    Wei, Wei-Zen
    CELLULAR IMMUNOLOGY, 2006, 240 (02) : 96 - 106
12345